Logo image of TVRD

TVARDI THERAPEUTICS INC (TVRD) Stock Fundamental Analysis

USA - NASDAQ:TVRD - US1407553072 - Common Stock

36.32 USD
-0.49 (-1.33%)
Last: 9/26/2025, 8:00:00 PM
36.32 USD
0 (0%)
After Hours: 9/26/2025, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TVRD. TVRD was compared to 196 industry peers in the Pharmaceuticals industry. The financial health of TVRD is average, but there are quite some concerns on its profitability. TVRD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TVRD has reported negative net income.
In the past year TVRD has reported a negative cash flow from operations.
In the past 5 years TVRD reported 4 times negative net income.
TVRD had a negative operating cash flow in each of the past 5 years.
TVRD Yearly Net Income VS EBIT VS OCF VS FCFTVRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of TVRD (-115.70%) is worse than 78.57% of its industry peers.
Industry RankSector Rank
ROA -115.7%
ROE N/A
ROIC N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TVRD Yearly ROA, ROE, ROICTVRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

TVRD has a better Gross Margin (86.08%) than 90.31% of its industry peers.
TVRD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TVRD Yearly Profit, Operating, Gross MarginsTVRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

4

2. Health

2.1 Basic Checks

TVRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TVRD has more shares outstanding
The number of shares outstanding for TVRD has been increased compared to 5 years ago.
There is no outstanding debt for TVRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TVRD Yearly Shares OutstandingTVRD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
TVRD Yearly Total Debt VS Total AssetsTVRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -23.96, we must say that TVRD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TVRD (-23.96) is worse than 82.65% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.96
ROIC/WACCN/A
WACC9.86%
TVRD Yearly LT Debt VS Equity VS FCFTVRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TVRD has a Current Ratio of 32.48. This indicates that TVRD is financially healthy and has no problem in meeting its short term obligations.
TVRD has a Current ratio of 32.48. This is amongst the best in the industry. TVRD outperforms 98.98% of its industry peers.
TVRD has a Quick Ratio of 31.73. This indicates that TVRD is financially healthy and has no problem in meeting its short term obligations.
TVRD has a better Quick ratio (31.73) than 98.98% of its industry peers.
Industry RankSector Rank
Current Ratio 32.48
Quick Ratio 31.73
TVRD Yearly Current Assets VS Current LiabilitesTVRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

2

3. Growth

3.1 Past

TVRD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.11%.
The Revenue for TVRD has decreased by -49.96% in the past year. This is quite bad
TVRD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.21% yearly.
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.49%
Revenue 1Y (TTM)-49.96%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, TVRD will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.82% on average per year.
Based on estimates for the next years, TVRD will show a very negative growth in Revenue. The Revenue will decrease by -18.92% on average per year.
EPS Next Y98.33%
EPS Next 2Y40.17%
EPS Next 3Y24.93%
EPS Next 5Y13.82%
Revenue Next Year-82.49%
Revenue Next 2Y-86.23%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TVRD Yearly Revenue VS EstimatesTVRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TVRD Yearly EPS VS EstimatesTVRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TVRD. In the last year negative earnings were reported.
Also next year TVRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TVRD Price Earnings VS Forward Price EarningsTVRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVRD Per share dataTVRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

TVRD's earnings are expected to grow with 24.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.17%
EPS Next 3Y24.93%

More info and screens

0

5. Dividend

5.1 Amount

TVRD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TVARDI THERAPEUTICS INC

NASDAQ:TVRD (9/26/2025, 8:00:00 PM)

After market: 36.32 0 (0%)

36.32

-0.49 (-1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners20.85%
Inst Owner ChangeN/A
Ins Owners19.12%
Ins Owner Change100%
Market Cap340.68M
Analysts84.62
Price Target58.29 (60.49%)
Short Float %12.77%
Short Ratio24.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)49.63%
Min Revenue beat(2)-10.63%
Max Revenue beat(2)109.89%
Revenue beat(4)2
Avg Revenue beat(4)34.26%
Min Revenue beat(4)-17.21%
Max Revenue beat(4)109.89%
Revenue beat(8)4
Avg Revenue beat(8)5.44%
Revenue beat(12)7
Avg Revenue beat(12)0.17%
Revenue beat(16)9
Avg Revenue beat(16)-1.11%
PT rev (1m)1.27%
PT rev (3m)19.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.82%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 45
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-78.48
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-3.82
FCFYN/A
OCF(TTM)-3.8
OCFYN/A
SpS0.81
BVpS-0.86
TBVpS-0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.08%
FCFM N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.48
Quick Ratio 31.73
Altman-Z -23.96
F-Score6
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)492.59%
Cap/Depr(5y)332.09%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.49%
EPS Next Y98.33%
EPS Next 2Y40.17%
EPS Next 3Y24.93%
EPS Next 5Y13.82%
Revenue 1Y (TTM)-49.96%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-100%
Revenue Next Year-82.49%
Revenue Next 2Y-86.23%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1Y76.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.9%
EBIT Next 3Y10.58%
EBIT Next 5YN/A
FCF growth 1Y59.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.45%
OCF growth 3YN/A
OCF growth 5YN/A